Abstract:Therapeutically targeting senescent cells seems to be an interesting perspective in treating chronic lung diseases, which are often associated with human aging. The combination of the drug dasatinib and the polyphenol quercetin is used in clinical trials as a senolytic, and the first results point to the relief of physical dysfunction in patients with idiopathic pulmonary fibrosis. In this work, we tested new combinations of drugs and polyphenols, looking for senolytic activity using human lung fibroblasts (MRC-5 cell line) with induced senescence. We researched drugs, such as azithromycin, rapamycin, metformin, FK-506, aspirin, and dasatinib combined with nine natural polyphenols, namely caffeic acid, chlorogenic acid, ellagic acid, ferulic acid, gallic acid, epicatechin, hesperidin, quercetin, and resveratrol. We found new effective senolytic combinations with dasatinib and ellagic acid and dasatinib and resveratrol. Both drug combinations increased apoptosis, reduced BCL-2 expression, and increased caspase activity in senescent MRC-5 cells. Ellagic acid senolytic activity was more potent than quercetin, and resveratrol counteracted inflammatory cytokine release during senolysis in vitro. In conclusion, dasatinib and ellagic acid and dasatinib and resveratrol present in vitro senolytic potential like that observed for the combination in clinical trials of dasatinib and quercetin, and maybe they could be future alternatives in the senotherapeutic field.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to find new drug combinations with anti - aging activity in human lung fibroblasts (MRC - 5 cell line). Specifically, the researchers tested combinations of multiple drugs and natural polyphenols to explore whether they can effectively eliminate senescent cells and thus may be used to treat chronic lung diseases related to aging, such as idiopathic pulmonary fibrosis (IPF). ### Background As people age, cell senescence becomes an important factor in chronic lung diseases. These diseases include lung cancer, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Cell senescence not only leads to cell - cycle arrest, but also affects the function of surrounding cells by secreting pro - inflammatory factors and growth factors (known as the senescence - associated secretory phenotype, SASP). Therefore, therapies targeting senescent cells (such as senolytic drugs) are considered as potential methods for treating these diseases. ### Research Objectives 1. **Explore new anti - aging drug combinations**: The researchers tested combinations of multiple drugs and natural polyphenols to find new drug combinations with anti - aging activity. 2. **Evaluate the effects of drug combinations**: Evaluate the anti - aging effects of these combinations in MRC - 5 cells induced to senescence through experiments, including changes in apoptosis, BCL - 2 expression and caspase activity. 3. **Compare the effects of different combinations**: Compare the effects of different drug combinations to find the most effective combination. ### Main Findings 1. **Effective anti - aging combinations**: The study found that the combination of dasatinib with ellagic acid and resveratrol has a significant anti - aging effect. These combinations can increase apoptosis, reduce BCL - 2 expression, and increase caspase activity. 2. **Compare the effects of different combinations**: Compared with the known combination of dasatinib and quercetin, the combination of dasatinib and ellagic acid can achieve a similar anti - aging effect at a lower concentration, and resveratrol can effectively inhibit the release of inflammatory cytokines. 3. **Mechanism research**: Further mechanism research shows that these combinations mainly eliminate senescent cells by promoting apoptosis rather than necrosis. ### Conclusions The combination of dasatinib with ellagic acid and resveratrol shows similar anti - aging potential in vitro as the combination of dasatinib and quercetin used in clinical trials, which provides a new direction for future pre - clinical and clinical trials, especially in the treatment of lung diseases related to aging. ### Keywords - dasatinib - quercetin - ellagic acid - resveratrol - senotherapeutic - cell senescence This paper provides important experimental evidence for the development of new anti - aging drug combinations and is expected to provide new treatment strategies for treating chronic lung diseases related to aging in the future.

Researching New Drug Combinations with Senolytic Activity Using Senescent Human Lung Fibroblasts MRC-5 Cell Line

Addition of Polyphenols to Drugs: The Potential of Controlling "Inflammaging" and Fibrosis in Human Senescent Lung Fibroblasts In Vitro

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Effect of Combined Dasatinib and Fisetin Treatment on Senescent Cell Clearance in Monkeys

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Senolytic drugs: from discovery to translation

Modulating in vitro lung fibroblast activation via senolysis of senescent human alveolar epithelial cells

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data

Connectivity Map and perturbation-based sensitivity analysis identifies MEK inhibitors as senolytics in human lung fibroblasts

Senolytics and Dietary Phytochemicals: Exploring Anti-Aging Strategies and Mechanisms in Aging and Disease

Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration

Effects of senolytic drugs on human mesenchymal stromal cells

Quercetin induces senolysis of doxorubicin-induced senescent fibroblasts by reducing autophagy, preventing their pro-tumour effect on osteosarcoma cells

In Vitro Investigation of Therapy-Induced Senescence and Senescence Escape in Breast Cancer Cells Using Novel Flow Cytometry-Based Methods

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Combined dasatinib and quercetin treatment contributes to skin rejuvenation through selective elimination of senescent cells in vitro and in vivo

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence

An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis